BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17133107)

  • 1. Medullary thyroid cancer: therapeutic targets and molecular markers.
    Ball DW
    Curr Opin Oncol; 2007 Jan; 19(1):18-23. PubMed ID: 17133107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
    Santarpia L; Ye L; Gagel RF
    J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of medullary thyroid cancer.
    Ball DW
    Minerva Endocrinol; 2011 Mar; 36(1):87-98. PubMed ID: 21460789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medullary thyroid carcinoma and biomarkers: past, present and future.
    van Veelen W; de Groot JW; Acton DS; Hofstra RM; Höppener JW; Links TP; Lips CJ
    J Intern Med; 2009 Jul; 266(1):126-40. PubMed ID: 19522831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic approaches to treat medullary thyroid carcinoma.
    Schlumberger M; Carlomagno F; Baudin E; Bidart JM; Santoro M
    Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):22-32. PubMed ID: 18084343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
    Cerrato A; De Falco V; Santoro M
    J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medullary thyroid carcinoma.
    Leboulleux S; Baudin E; Travagli JP; Schlumberger M
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):299-310. PubMed ID: 15355445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New molecular targeted therapies in thyroid cancer.
    Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
    Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
    Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
    Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of medullary thyroid carcinoma.
    Jiménez C; Hu MI; Gagel RF
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medullary thyroid cancer: molecular biology and novel molecular therapies.
    Cakir M; Grossman AB
    Neuroendocrinology; 2009; 90(4):323-48. PubMed ID: 19468197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.
    Rodríguez-Antona C; Pallares J; Montero-Conde C; Inglada-Pérez L; Castelblanco E; Landa I; Leskelä S; Leandro-García LJ; López-Jiménez E; Letón R; Cascón A; Lerma E; Martin MC; Carralero MC; Mauricio D; Cigudosa JC; Matias-Guiu X; Robledo M
    Endocr Relat Cancer; 2010 Mar; 17(1):7-16. PubMed ID: 19776290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
    Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
    J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope.
    Deshpande HA; Gettinger SN; Sosa JA
    Curr Opin Oncol; 2008 Jan; 20(1):19-24. PubMed ID: 18043252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
    van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
    Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medullary thyroid cancer: a promising model for targeted therapy.
    Torino F; Paragliola RM; Barnabei A; Corsello SM
    Curr Mol Med; 2010 Oct; 10(7):608-25. PubMed ID: 20712590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic advances in the management of progressive thyroid cancer.
    Woyach JA; Shah MH
    Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medullary thyroid cancer: early detection and novel treatments.
    Roman S; Mehta P; Sosa JA
    Curr Opin Oncol; 2009 Jan; 21(1):5-10. PubMed ID: 19125012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma.
    Messina M; Robinson BG
    Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):290-301. PubMed ID: 17315037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medullary thyroid carcinoma: surgical treatment advances.
    Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.